--
Richard Chudacoff, MD
-----Original Message-----
From: ob-gyn-l@obgyn.net [mailto:ob-gyn-l@obgyn.net] On Behalf Of Braun, R.
Daniel
Sent: Monday, November 29, 2004 1:21 PM
To: Multiple recipients of list OB-GYN-L
Subject: Re: Evista
But shouldn't the premenopausal patients estrogen do everything that
raloxiphene does for the bone?
R. Daniel Braun, MD
"If everyone likes you, you're doing something wrong."
Kinky Friedman
I believe a self-righteous liberal or conservative with a cause is more
dangerous than a Hell's Angel with an attitude.
Andy Rooney
-----Original Message-----
From: ob-gyn-l@obgyn.net [mailto:ob-gyn-l@obgyn.net] On Behalf Of
Douglas Krell
Sent: Monday, November 29, 2004 12:59 PM
To: Multiple recipients of list OB-GYN-L
Subject: Re: Evista
Richard, Ana et al...,
While there are no indications for the use of Evista in premenopausal
women
(raloxifene competes with endogenous estrogen for estrogen receptor
binding
sites), the use of raloxifene for the treatment of osteopenia in
postmenopausal women is an important strategy in the scheme of the
ultimate
goal of preventing fractures in women due to bone loss .
The National Osteoporosis Foundation as well the International
Osteoporosis
Foundation recommends treatment with raloxifiene for women with
demonstrated
osteopenia when there are two additional risk factors for osteoporosis
present; Family history, caucasian, smoking, low calcium intake, body
weight
under 125lbs....just about all of our patients. These recommendations
are
published on their web sites
The NORA (National Osteoporosis Risk Assessment) trial recently
published
with over 200,000 women studied in outpatient settings found that of the
women who sufferred a fracture, over 80% had OSTEOPENIA...not
osteoporosis.
So there is some reason to consider treating these women.
Moreover, raloxifiene is the only therapy I'm aware of that has been
proven
to prevent fracture in randomized, doubly blinded trials when studied
prospectively in the patient with osteopenia. Everyone else has only
BMD
data.
Douglas Krell MD FACOG
>From: "Richard Chudacoff, MD" <rchudacoff@mylinuxisp.com>
>Reply-To: ob-gyn-l@obgyn.net
>To: Multiple recipients of list OB-GYN-L <ob-gyn-l@dns.obgyn.net>
>Subject: Evista in premenopausal women
>Date: Mon, 29 Nov 2004 09:32:33 -0600
>
>Is there any indication for Evista in premenopausal women? I have two
>patients from the same FP now, who is giving it for osteopenia (not a
>condition I recognize as needing treatment.)
>
>Richard Chudacoff, MD
>
>Chudacoff OB & GYN, PA
>
>15200 Soutwest Freeway #270
>
>Sugar Land, TX 77478
>
>tel: 281-277-3900
>
>fax: 281-277-3901
>
>Email: Richard.Chudacoff@obgyn.net
>
> rchudacoff@mylinuxisp.com
>
